000165621 001__ 165621
000165621 005__ 20260112132217.0
000165621 0247_ $$2doi$$a10.3389/fimmu.2021.659018
000165621 0248_ $$2sideral$$a147104
000165621 037__ $$aART-2021-147104
000165621 041__ $$aeng
000165621 100__ $$aMartín-Sánchez, Esperanza
000165621 245__ $$aImmunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
000165621 260__ $$c2021
000165621 5203_ $$aInformation on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17 immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868 COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2 infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly different from those of age-matched healthy donors but generally similar to those of patients with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was characterized by significantly lower percentages of all immune cell-types except neutrophils and circulating plasma cells, and was significantly associated with severe disease. Reduced B-cell percentage was most strongly associated with risk of death. On multivariate analysis incorporating age and comorbidities, B-cell and non-classical monocyte percentages were independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts. Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk immune biomarkers for risk-stratification of COVID-19 patients.
000165621 540__ $$9info:eu-repo/semantics/closedAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000165621 590__ $$a8.787$$b2021
000165621 591__ $$aIMMUNOLOGY$$b35 / 162 = 0.216$$c2021$$dQ1$$eT1
000165621 592__ $$a2.331$$b2021
000165621 593__ $$aImmunology and Allergy$$c2021$$dQ1
000165621 593__ $$aImmunology$$c2021$$dQ1
000165621 594__ $$a9.8$$b2021
000165621 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165621 700__ $$aGarcés, Juan José
000165621 700__ $$aMaia, Catarina
000165621 700__ $$aInogés, Susana
000165621 700__ $$aLópez-Díaz de Cerio, Ascensión
000165621 700__ $$aCarmona-Torre, Francisco
000165621 700__ $$0(orcid)0000-0003-0777-3850$$aMarin-Oto, Marta
000165621 700__ $$aAlegre, Félix
000165621 700__ $$aMolano, Elvira
000165621 700__ $$aFernández-Alonso, Mirian
000165621 700__ $$aPérez, Cristina
000165621 700__ $$aBotta, Cirino
000165621 700__ $$aZabaleta, Aintzane
000165621 700__ $$aAlcaide, Ana Belén
000165621 700__ $$aLandecho, Manuel F.
000165621 700__ $$aRua, Marta
000165621 700__ $$aPérez-Warnisher, Teresa
000165621 700__ $$aBlanco, Laura
000165621 700__ $$aSarvide, Sarai
000165621 700__ $$aVilas-Zornoza, Amaia
000165621 700__ $$aAlignani, Diego
000165621 700__ $$aMoreno, Cristina
000165621 700__ $$aPineda, Iñigo
000165621 700__ $$aSogbe, Miguel
000165621 700__ $$aArgemi, Josepmaria
000165621 700__ $$aPaiva, Bruno
000165621 700__ $$aYuste, José Ramón
000165621 773__ $$g12 (2021), 659018 [13 pp.]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000165621 8564_ $$s3319613$$uhttps://zaguan.unizar.es/record/165621/files/texto_completo.pdf$$yVersión publicada
000165621 8564_ $$s2664513$$uhttps://zaguan.unizar.es/record/165621/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165621 909CO $$ooai:zaguan.unizar.es:165621$$particulos$$pdriver
000165621 951__ $$a2026-01-12-11:11:23
000165621 980__ $$aARTICLE